Stem cell shot aims to reverse frailty in seniors
Symptom relief
Not yet recruiting
This early-stage study tests the safety of a new stem cell treatment called HeXell-2020 in 12 older adults (ages 60-85) with mild to moderate frailty. Participants receive a single intravenous dose, and researchers monitor for side effects and changes in physical function like wa…
Phase: PHASE1 • Sponsor: Hexun Biosciences Co., LTD. • Aim: Symptom relief
Last updated May 17, 2026 09:49 UTC